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EDITORIAL

A Tale of Two Failures: A Guide to Shared
Decision-Making for Heart and Renal Failure

H

eart failure and kidney disease are common and
rapidly growing conditions in the United States. It
is estimated that there are currently 6.5 million adults in
the United States1 and 23 million adults worldwide who
suffer from heart failure.2 Approximately 30 million
Americans have evidence of chronic kidney disease
(CKD).3 The presence of either condition is associated
with a higher morbidity and mortality than the general
population. Approximately 40% of patients with endstage renal disease (ESRD) have heart failure. In this
group, 27% will die from heart failure and associated complications.4 Having both diseases can complicate treatment for either condition. Even with advanced therapies
such as hemodialysis (HD) and left ventricular assist devices (LVAD), these patients face limited prognosis and
diminished function. Clinical nephrologists and cardiologists struggle with how to communicate prognostic
worries to guide treatment decisions in this medically
complex population. We here argue that shared decisionmaking (SDM) is the framework that in which physicians
and patients work together to determine the best treatment plan based on prognostic information, patient
values, and priorities.
LVADs are implanted as a bridge to heart transplant or
as destination therapy in end-stage heart failure (ESHF).
The REMATCH trial validated LVADs as destination therapy by demonstrating that patients who underwent
LVAD implantation had a 1-year survival of 51%, and
LVAD implantation conferred a 27% absolute reduction
in 1-year mortality when compared with maximal medical management.5 Long-term dialysis (hemodialysis and
peritoneal) is problematic when it comes to destination
LVAD; most institutions consider LVAD implantation to
be contraindicative in patients on dialysis, in part, due
to the difﬁculty of placing these patients in outpatient
dialysis units.6 Certainly, LVAD therapy has not proven
beneﬁcial in all populations. The 1-year survival rate after
LVAD implantation has since improved to nearly 80% in
the general population,7-11 but this does not appear to
be the case when both ESRD and ESHF are present.
Bansal and colleagues recently examined United States

Renal Data System data and a 5% sample of Medicare
beneﬁciaries without ESRD and determined that 51.6%
of ESRD patients who had received LVADs died during
their index hospitalization compared with only 4.2% of
the LVAD recipients from the Medicare sample.7 The median time to death in the ESRD group was 16 days (interquartile range, 2-447 days) compared with 2125 days
(interquartile range, 565-3850) for those without ESRD.7
In most centers, the presence of CKD deﬁned as a sustained eGFR , 30 mL/min/1.73 m2 is considered a relative
contraindication to LVAD.6 It is widely believed that renal
impairment secondary to cardiorenal syndrome (CRS),
particularly CRS type II, is most amenable to improvement with LVAD therapy. A single-center study compared
outcomes after LVAD placement among patients with a
baseline eGFR , 40 mL/min/1.73 m2 and .40 mL/min/
1.73 m2 in patients without evidence for chronic intrinsic
(e.g., glomerulonephritis, diabetic kidney disease, or
decreased function from aging) or structural disease
who were not on dialysis. At 1 and 12 months after
LVAD placement, survival in the ,40 mL/min/1.73 m2
group was 53% and 39%, respectively. Respective survival
data in the .40 mL/min/1.73 m2 group were 99% and
82%.11 Furthermore, in a multicenter, retrospective cohort
study, a higher CKD stage was associated with greater
risk and severity of AKI, deﬁned by KDIGO AKI criteria,
after LVAD implantation.9 In multivariate analysis, eGFRs
of 30–59 mL/min/1.73 m2 at baseline had a hazard ratio for
mortality of 2.24 (P ¼ 0.008), and an eGFR , 30 mL/min/
1.73 m2 had a hazard ratio of 2.67 (P ¼ 0.011).9 In ESRD
and CKD populations, the mortality risk seems concentrated in the ﬁrst 3 months after LVAD implantation.
The occurrence of AKI after LVAD implantation was associated with increased mortality at 30 days (26.3% [AKI
stage 2] vs 8.3% [no AKI]) and at 1 year (51% [AKI stage
2] vs 18.7% [no AKI]).9 Those who required dialysis after
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implantation had the worst prognosis at 30 days, with a
mortality rate of 30.3% with renal replacement therapy
(RRT) vs 10.6% without RRT. The mortality difference
was also present at 1 year after implantation (62.3%
[RRT] vs 24% [without RRT]).9
Renal impairment, whether it is secondary to CRS or
AKI of other cause, is associated with a more limited survival in patients who receive an LVAD than in non-LVAD
patients with similar degrees of kidney dysfunction. Thus,
for patients with CRS and AKI (who are also potential
candidates for LVAD), it is important that patients have
an informed understanding of what to expect after
LVAD placement and how this compares with the general
population. This shared decision-making (SDM) model,
which has been endorsed by both the American Society
of Nephrology and the Renal Physicians Association as
the preferred approach to dialysis decision-making, has
both the physician and the patient assume an active
role.12 The clinician educates the patient on the condition/procedure, the risks and prognosis, and addresses
any concerns the patient may have. Then, the physician
seeks input from the patient about his/her goals and
values. If the patient is interested, the physician may
also make a recommendation about what treatment plan
will best achieve desired goals. Ultimately, the patient is
encouraged to ask questions and make the ﬁnal decision.
In this way, both patient and physician share the decisionmaking process. SDM can be an effective way to prepare
patients for what may come and empowers them to take
control of their health.
The SDM model begins with prognostic information.
Physicians often worry that disclosing prognosis will
take away hope. On the contrary, in a study of advanced
CKD patients, 97% of patients expressed a desire to
know about life expectancy on dialysis. Over half of patients rated this knowledge as “an absolute need to
know”13 for treatment decisions. A Canadian study of
CKD stages 4 and 5D patients revealed that most patients
had a poor knowledge of their illness trajectory and that
only 10% of these patients discussed prognosis or endof-life care with their nephrologist.14
Providing patients with prognostic information is integral to SDM. Because different patients may hold different
values as to what is important to them, this information
can shape treatment decisions in a variety of different
ways. First, patients who do not discuss prognosis with
their providers are more likely to both overestimate prognosis and choose more aggressive therapies.15 Second, patients may hold different values as to what is important to
them. In a choice experiment with patients approaching
ESRD, many were willing to trade a shorter life expectancy to reduce the burden of greater hospitalizations to
gain more independence.16 Improved prognostic awareness may better match treatment decisions with patient
priorities. Third, most patients interpret ‘survival’ as
living well and quality of life rather than just living
longer.17 Therefore, prognostic information should
address survival as well as quality of life.

Understanding prognosis after LVAD placement in patients with ESHF, advanced CKD, ESRD, and AKI on a
population level can help to inform discussions with patients. Although estimating prognosis in individual patients can be challenging, several prognostication tools
are available to support practice in this area. One tool
is the “surprise question”, that is, “Would I be surprised
if this patient will die in the next year?” When providers
caring for patients on dialysis were asked this question,
29.4% of patients for whom the provider would not
have been surprised if the patient died in the next year
had died at 1 year, compared with only 10% of other patients.18 The surprise question has also been recently
validated in the CKD stages 4 and 5 population with
similar results,19 suggesting that physicians should
follow their clinical intuition. The surprise question has
been validated in heart failure as a tool for triggering
referral to palliative care.20,21 Another prognostication
tool is the Charlson Comorbidity Index, which is a
prognostic scoring system based on age and the
presence of speciﬁc comorbid conditions.22 Mortality at
1 year ranges from 3–49% among patients with the
lowest and highest Charlson scores.22 For patients with
heart failure, prognosis can be estimated using the Seattle Heart Failure Model (SHFM), a calculator of projected
survival at baseline and after interventions for patients
with heart failure. This model is based on patient age,
echocardiographic parameters, medications, and New
York Heart Association (NYHA) Functional Classiﬁcation and yields 1-, 2-, and 5-year survival data and
mean life expectancy.23
Prognosis is usually given to patients in survival percentages or periods of time and ideally should address
the uncertainty around such estimates.24 Smith and colleagues suggest 3 central tasks to manage uncertainty.
The ﬁrst is to normalize the uncertainty of prognosis,
thus to reset expectations by helping the patient and family understand that we do not have deﬁnitive answers.25
The second task addresses the surrogates’ and patients’
emotions surrounding the uncertainty of the prognosis.
This is performed by acknowledging the emotions and
the difﬁculty surrounding uncertainty. Finally, the third
task is to help manage the effect of uncertainty on the patients’ and families’ abilities to live in the moment. Based
on speciﬁc, prognostic information and given this uncertainty, one may present prognosis as ranges such as hours
to days, days to weeks, weeks to months, months to years,
or years.24
When attempting to guide patients with ESRD and
ESHF, there are good communication tools to help
physicians to more effectively convey information.
The “Ask-Tell-Ask” method26-28 promotes good
communication between providers and their patients
and helps show patients that the provider is willing to
listen and engage in their care.26 The ﬁrst “Ask” is an
open-ended question that gauges the patient’s level of
understanding and readiness to engage in the conversation.26-28 The question can be, “What is your
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understanding of your heart and kidney condition?” It
can also be, “What have your doctors told you about
your kidney (and/or) heart condition?” How patients
answer these kinds of questions lends insight into
their levels of knowledge, understanding, hopes and
fears, and readiness to enter “the conversation”. Next,
before proceeding to “tell” the patient, it is important
to ﬁrst ask their permission to provide the
information. For example, “Is it okay for me to tell
you what I know?”28 If the patient is willing, then the
provider can begin to share information in the context
of what they have learned from the patient about their
level of understanding using straightforward language
targeted to their education level and in a way that is sensitive to the patient’s emotional state.26-28 It is important
to avoid informational overload and aim to provide no
more than 3 new pieces of information in short, easily
digestible chunks.26,28
The objective of the ﬁnal “Ask” is to assess the patients’
understanding and offer an opportunity for questions.26,28
The question can be, “We have just discussed a lot of new
information, to make sure we are on the same page, can
you tell me your understanding of the problem?” After
reviewing anything that patients may not have
understood, the provider should always conclude by
asking and addressing any further questions from the
patient. In addition to the challenges of information
sharing, discussing prognosis is often a time of signiﬁcant
negative emotion, including anxiety, sadness, and shock.
Although health-care providers often cannot “ﬁx” the
causes of these emotions, they can show emotional support
by being present, listening, and expressing empathy. Expressing empathy is simply acknowledging the presence
of emotion without judgment (e.g., “I can only imagine
how hard this is.”).28-30 Research clearly demonstrates
that health-care providers can learn to communicate in a
more empathic fashion, and several communication tools
have been published to support empathic conversations between patients and providers.26-29
Excellent communication is essential to SDM. The evidence available implies that patients with CKD, AKI,
and ESRD do worse than the general population who
develop ESHF and CRS. The prognosis for ESRD is particularly bad. As we learn more about the effects that CKD,
AKI, and ESRD have on the morbidity and mortality of
patients who develop CRS and ESHF, communicating
this with patients will become paramount. Before entering
a conversation, understanding the mortality risks and using clinical and prognostic tools to gauge overall prognosis is essential. Using appropriately designed
communication tools, clinicians, not only nephrologists,
can more effectively facilitate patient's appreciation of
their conditions, options, and expectations. When uncertainty exists, a time-limited trial of renal replacement therapy may be warranted. Putting the tools into practice
promotes improved provider–patient communication,
and optimizes shared decision-making care. Using a
shared decision-making model as discussed will reduce
the health-care burden of patients who dually suffer
from cardiac and renal failure.

Without health life is not life; it is only a state of languor and
suffering—an image of death.—Francois Rabelais
(1494 – 1553)
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